The 20 Best Non-Small Cell Lung Cancer (NSCLC) Doctors Near Me

Gary Schwartz is a Hematologist Oncology provider in Cleveland, Ohio. Dr. Schwartz has been practicing medicine for over 47 years and is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Fibrosarcoma, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

Suresh Ramalingam is an Oncologist in Atlanta, Georgia. Dr. Ramalingam has been practicing medicine for over 34 years and is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Charu Aggarwal is an Oncologist in Philadelphia, Pennsylvania. Dr. Aggarwal is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Aggarwal is currently accepting new patients.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Dr. O'Shaughnessy is a Medical Oncologist that focuses on breast cancer prevention and treatment. She founded The School of Breast Oncology, a program providing a curriculum-based program focused exclusively on breast cancer clinical management. Dr. O'Shaughnessy attended medical school at Yale University School of Medicine in New Haven, CT. She then completed her Internal Medicine residency at Massachusetts General Hospital in Boston, MA and a Medical Oncology fellowship at National Cancer Institute in Bethesda, MD. She is co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center and a member of the Scientific Advisory Board for US Oncology Research Network. Dr. O'shaughnessy is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Inflammatory Breast Cancer, and Tissue Biopsy.

I specialize in the care of patients with urologic cancers – mainly prostate cancer, kidney cancer, bladder cancer and testicular cancer. A cancer diagnosis is one of the scariest things that can happen to someone. For many of our patients, they don’t necessarily feel different or look different, but they are scared to death. The most important thing you can get from Duke is real understanding of your particular case and what your options are. Knowledge is so reassuring and empowering for patients, especially those recently diagnosed with cancer. When you’re first diagnosed, you have to put your trust in a care team, and that’s hard to do if you don’t already know them. As the largest cancer center in North Carolina, Duke has great reputation and experience, which helps many patients chose Duke for their care. But we grow and develop our trust with patients because of who we are as people and how much expertise and care we bring to each case. Dr. George is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

Mehmet Bilen is an Oncologist in Atlanta, Georgia. Dr. Bilen has been practicing medicine for over 18 years and is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Tissue Biopsy.

I am a part of the thoracic oncology program. I work with patients who have cancers of the lung, which includes non-small cell lung cancer, small cell lung cancer, and mesothelioma. My focus is on clinical care, clinical trials, and developing new therapies for these diseases. When I first meet with a patient, I want them to understand what their diagnosis is, because there are actually multiple diagnoses of lung cancer and each are treated differently. Then I discuss with a patient whether they are a candidate for therapies such as molecular therapy or immunotherapy, and make sure they have a clear understanding of the treatment plan. There are some very promising new therapies for these diseases and we are fortunate to have those available to patients here at Duke. That’s one of the unique things we offer as an academic medical center. Dr. Stinchcombe is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

My goals are to develop and provide treatments that prolong and improve quality of the lives of patients with aggressive prostate, kidney, bladder, and testicular cancer. This work involves the direct care of patients in the clinic and clinical research involving the development of new therapies in clinical trials. I devote over half of my time to understanding how prostate cancer spreads and resists therapies, as well as methods of measuring this biology in patients, which may lead to improved therapies designed to block this process. Outside of work, I have a busy family life with three children, and a wife who is a Duke pediatrician. I enjoy playing soccer and hiking. Dr. Armstrong is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Prostatectomy.

Adam M. Brufsky, MD, PhD, FACP, is professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine's Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women's Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; associate director for clinical investigations at UPMC Hillman Cancer Center; and codirector of the Comprehensive Breast Cancer Center.Dr. Brufsky is board-certified in internal medicine and medical oncology. He earned a medical and doctor of philosophy degrees from the University of Connecticut School of Medicine in Farmington, Conn.; completed a residency at Brigham and Women's Hospital, Harvard Medical School, and a fellowship at Dana-Farber Cancer Institute.Dr. Brufsky is a member of professional organizations, such as American Medical Association, Massachusetts Medical Society, American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, Allegheny County Medical Society, Pennsylvania Medical Society, and Pennsylvania Oncologic Society. An active researcher, Dr. Brufsky has numerous abstracts and research articles in leading journals, and is principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army - Breast Cancer Research Program. Dr. Brufsky is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Gastrostomy.

Balazs Halmos, MD received his medical degree summa cum laude from Semmelweis University in Budapest, Hungary. He completed an internal medicine residency program at St. Dr. Halmos is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Liza C. Villaruz, MD, is board-certified in medical oncology and hematology at UPMC Hillman Cancer Center, and she specializes in lung cancer and thoracic malignancies. Dr. Villaruz is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC).

I am a medical oncologist and researcher who specializes in treating patients with lung cancer and head and neck cancer. I’ve been at Duke for eight years. I first realized I wanted to become a doctor in graduate school, because it gave me the opportunity to practically apply scientific evidence to help others. What I love most about my job is working with our research and clinical staff to come up with new and hopeful therapies for patients. When a patient comes to see me, I look at their past and current medical history, review their lab tests, and then work with a team to figure out which treatment would work best for them. If a patient comes from far away, we try to make sure we can fit in visits with all the relevant specialists before they leave. Outside of work, I enjoy exercising with friends and spending time with my children at their various activities. Dr. Ready is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

Bradley Carthon is an Oncologist in Atlanta, Georgia. Dr. Carthon has been practicing medicine for over 21 years and is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Prostatectomy.

Omer Kucuk is an Oncologist in Atlanta, Georgia. Dr. Kucuk has been practicing medicine for over 51 years and is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Prostatectomy.

Lecia Van Dam Sequist is an Oncologist in Waltham, Massachusetts. Dr. Van Dam Sequist is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy.

Corey Langer is an Oncologist in Philadelphia, Pennsylvania. Dr. Langer is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Langer is currently accepting new patients.

Scott Antonia is an Oncologist in Durham, North Carolina. Dr. Antonia has been practicing medicine for over 37 years and is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Jacob Sands is an Oncologist in Boston, Massachusetts. Dr. Sands is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

Roger Cohen is an Oncologist in Philadelphia, Pennsylvania. Dr. Cohen is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Tissue Biopsy, and Endoscopy. Dr. Cohen is currently accepting new patients.